PMID- 29244162
OWN - NLM
STAT- MEDLINE
DCOM- 20180518
LR  - 20220330
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 57
IP  - 3
DP  - 2018 Mar 1
TI  - Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways 
      for peripheral psoriatic arthritis: a network meta-analysis.
PG  - 563-571
LID - 10.1093/rheumatology/kex452 [doi]
AB  - OBJECTIVE: To investigate the comparative efficacy, safety and tolerability of 
      IL-6, IL-12/23 and IL-17 inhibitors for patients with active PsA. METHODS: 
      Randomized controlled trials evaluating the efficacy, safety and tolerability of 
      IL-6, IL-12/23 and IL-17 inhibitors were identified by a comprehensive systematic 
      literature review. Pairwise meta-analyses and Bayesian network meta-analyses 
      using the random effects model were performed to estimate pooled odds ratios 
      (ORs) and 95% credible intervals of attaining a 20% or 50% improvement in ACR 
      criteria (ACR20 and ACR50, respectively) across trials. RESULTS: Six trials were 
      identified that included 2411 participants and 11 treatments. Pairwise 
      meta-analysis showed that secukinumab, ustekinumab and ixekizumab demonstrated 
      superior efficacy over placebo in achieving an ACR20 and ACR50 response. However, 
      ixekizumab has a higher incidence of adverse events (AEs) than placebo. In 
      contrast, ustekinumab has a higher tolerability (less likely to be discontinued 
      due to AEs) than placebo. Network meta-analysis showed that secukinumab (300 mg 
      monthly) had the highest efficacy in achieving ACR20 and ACR50, whereas 
      clazakizumab (200 mg monthly), ustekinumab (45 mg 12 weekly) and secukinumab (150 
      mg monthly) had the lowest probability of having AEs, serious AEs and 
      intolerability, respectively. Considering the overall risk-benefit profile, 
      secukinumab (150 mg monthly) may offer an optimal balance for peripheral PsA 
      patients. CONCLUSION: Secukinumab may be the safest and most efficacious 
      short-term treatment for peripheral PsA among all the new biologics targeting 
      IL-6, IL-12/23 and IL-17 pathways.
CI  - (c) The Author 2017. Published by Oxford University Press on behalf of the British 
      Society for Rheumatology. All rights reserved. For Permissions, please email: 
      journals.permissions@oup.com
FAU - Wu, Dongze
AU  - Wu D
AD  - Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese 
      University of Hong Kong, Hong Kong.
FAU - Yue, Jiang
AU  - Yue J
AD  - Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese 
      University of Hong Kong, Hong Kong.
FAU - Tam, Lai-Shan
AU  - Tam LS
AD  - Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese 
      University of Hong Kong, Hong Kong.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biological Products)
RN  - 0 (Interleukin-12 Subunit p40)
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-6)
RN  - 4S38Z8RA9O (clazakizumab)
RN  - BTY153760O (ixekizumab)
RN  - DLG4EML025 (secukinumab)
RN  - FU77B4U5Z0 (Ustekinumab)
SB  - IM
CIN - Rheumatology (Oxford). 2018 Nov 1;57(11):2061-2062. PMID: 30239893
CIN - Rheumatology (Oxford). 2018 Nov 1;57(11):2062. PMID: 30239924
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy/metabolism
MH  - Bayes Theorem
MH  - Biological Products/*therapeutic use
MH  - Female
MH  - Humans
MH  - Interleukin-12 Subunit p40/*metabolism
MH  - Interleukin-17/*metabolism
MH  - Interleukin-6/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Network Meta-Analysis
MH  - Randomized Controlled Trials as Topic
MH  - Signal Transduction/*drug effects
MH  - Treatment Outcome
MH  - Ustekinumab/therapeutic use
EDAT- 2017/12/16 06:00
MHDA- 2018/05/19 06:00
CRDT- 2017/12/16 06:00
PHST- 2017/07/12 00:00 [received]
PHST- 2017/12/16 06:00 [pubmed]
PHST- 2018/05/19 06:00 [medline]
PHST- 2017/12/16 06:00 [entrez]
AID - 4735217 [pii]
AID - 10.1093/rheumatology/kex452 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2018 Mar 1;57(3):563-571. doi: 
      10.1093/rheumatology/kex452.